Partner Therapeutics
Partner Therapeutics is a privately held, integrated biotechnology company focused on development, manufacturing and commercialization of late-stage biologic therapeutics, with emphasis on oncology, immunomodulation and medical countermeasures. The company operates commercial biologics manufacturing, conducts sponsor- and investigator-initiated clinical development across oncology and respiratory indications (including COVID-19), engages with regulatory authorities, and pursues government and commercial partnerships to support advanced development and distribution.
Industries
Nr. of Employees
medium (51-250)
Partner Therapeutics
Products
Leukine (sargramostim)
A yeast‑derived recombinant human granulocyte‑macrophage colony‑stimulating factor (rhu GM‑CSF) developed and commercialized for hematology/oncology and other indications; investigated for pulmonary and immuno‑oncology indications and available via named‑patient programs ex‑US.
Zenocutuzumab (targeted antibody for NRG1 fusion-positive cancers)
A targeted antibody therapeutic licensed for U.S. commercialization to treat cancers harboring NRG1 gene fusions; evaluated in global multicenter clinical trials.
Leukine (sargramostim)
A yeast‑derived recombinant human granulocyte‑macrophage colony‑stimulating factor (rhu GM‑CSF) developed and commercialized for hematology/oncology and other indications; investigated for pulmonary and immuno‑oncology indications and available via named‑patient programs ex‑US.
Zenocutuzumab (targeted antibody for NRG1 fusion-positive cancers)
A targeted antibody therapeutic licensed for U.S. commercialization to treat cancers harboring NRG1 gene fusions; evaluated in global multicenter clinical trials.
Services
Commercial production and supply operations managed from a dedicated biologics manufacturing facility.
Operational and regulatory support for randomized and controlled clinical trials across oncology and respiratory indications, including protocol design, site initiation and study execution.
Management and execution of milestone-based government agreements to fund clinical development, manufacturing expansion and potential emergency use pathways.
U.S.-focused patient services program providing access and treatment support for marketed products.
Commercial production and supply operations managed from a dedicated biologics manufacturing facility.
Operational and regulatory support for randomized and controlled clinical trials across oncology and respiratory indications, including protocol design, site initiation and study execution.
Management and execution of milestone-based government agreements to fund clinical development, manufacturing expansion and potential emergency use pathways.
U.S.-focused patient services program providing access and treatment support for marketed products.
Expertise Areas
- Clinical trial management (Phase II/III, randomized, multicenter)
- Biologics manufacturing and scale-up
- Regulatory strategy and IND/authorization interactions (FDA/EMA)
- Immunomodulator therapeutics development (recombinant GM‑CSF)
Key Technologies
- Recombinant GM‑CSF therapeutics
- Monoclonal and multispecific antibody therapeutics
- GMP biologics manufacturing
- Inhalation (nebulized) drug delivery
News & Updates
FDA approval for use of recombinant human GM‑CSF to increase survival when initiated 48 hours after radiation exposure (H-ARS indication).
European Commission granted marketing authorization in the EU for sargramostim for treatment of hematopoietic sub‑syndrome of acute radiation syndrome.
FDA approval granted for a targeted antibody therapeutic for treatment of NRG1 fusion-positive cholangiocarcinoma following receipt of a Commissioner’s National Priority Voucher.
Completed $60 million Series A financing to support pipeline development and commercial operations.
Milestone-based Other Transaction Agreement with DoD to fund two randomized multi-center clinical trials, manufacturing expansion and potential emergency use authorization support for a recombinant GM‑CSF therapeutic in acute hypoxemic respiratory failure.
FDA approval for use of recombinant human GM‑CSF to increase survival when initiated 48 hours after radiation exposure (H-ARS indication).
European Commission granted marketing authorization in the EU for sargramostim for treatment of hematopoietic sub‑syndrome of acute radiation syndrome.
FDA approval granted for a targeted antibody therapeutic for treatment of NRG1 fusion-positive cholangiocarcinoma following receipt of a Commissioner’s National Priority Voucher.
Completed $60 million Series A financing to support pipeline development and commercial operations.
Milestone-based Other Transaction Agreement with DoD to fund two randomized multi-center clinical trials, manufacturing expansion and potential emergency use authorization support for a recombinant GM‑CSF therapeutic in acute hypoxemic respiratory failure.